NERVGEN PHARMA CORP.
WKN: A2QP3D | ISIN: CA64082X2032 | FSE: 9UA | TSX-V: NGEN | OTCQX: NGENF
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company’s initial focus is on spinal cord injury, Alzheimer’s disease and multiple sclerosis. Our lead product, NVG-291, entered a Phase 1 clinical trial in 2021. We plan to initiate our Phase 1b/2a clinical trials in patients in 2022.
More information: https://nervgen.com/
Speaker at IIF is Paul Brennan, CEO
|05/19/2022||07.20 am EST*|
01:20 pm CEST*
07.20 pm HKT*
|Paul Brennan, CEO||Join Zoom via Browser/App|
* CEST = Frankfurt, Paris | EST = New York, Toronto | HKT = HongKong, Perth, Singapore